M
36.29
0.79 (2.23%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Mineralys Therapeutics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.1
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.13 |
|
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 1.40% |
| 机构持股比例 | 103.83% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Catalys Pacific, Llc | 30 Sep 2025 | 8,903,838 |
| Samsara Biocapital, Llc | 30 Sep 2025 | 6,263,151 |
| Laurion Capital Management Lp | 30 Sep 2025 | 1,720,445 |
| Farallon Capital Management Llc | 30 Sep 2025 | 1,673,053 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 56.00 (HC Wainwright & Co., 54.31%) | 购买 |
| 中 | 55.00 (51.56%) | |
| 低 | 52.00 (Stifel, 43.29%) | 购买 |
| 平均值 | 54.33 (49.71%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 43.76 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Stifel | 19 Dec 2025 | 52.00 (43.29%) | 购买 | 36.83 |
| HC Wainwright & Co. | 12 Nov 2025 | 56.00 (54.31%) | 购买 | 47.33 |
| 30 Oct 2025 | 52.00 (43.29%) | 购买 | 41.12 | |
| Wells Fargo | 11 Nov 2025 | 55.00 (51.56%) | 购买 | 47.11 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合